Efficacy of a Naturally-derived Mouthrinse for Gingival Inflammation

A Randomized Multi-treatment/Controlled Double-blinded Study to Evaluate the Efficacy of a Naturally-derived Mouthrinse in the Treatment of Gingival Inflammation.

Sponsors

Lead Sponsor: Shaare Zedek Medical Center

Source Shaare Zedek Medical Center
Brief Summary

Gingivitis, defined as inflammation of the gingival tissues, has long been associated with bacterial accumulation [plaque] on the tooth surface adjacent to the gingiva, causing an inflammatory reaction. Experimental gingivitis in health adults can be induced by abstension from brushing teeth for 9 to 21 days, and can test the effects of numerous chemotherapeutic agents, rinses and toothpastes. Effective prevention of plaque accumulation can prevent destructive forms of periodontal disease. A recent link has been established between localized gingival inflammation and systemic inflammation and a number of disease processes. Periodontal disease may lead to elevated C-reactive protein [CRP], considered a potential risk factor for cardiovascular disease and stroke. It has been shown that reducing gingival inflammation is accompanied with a significant decrease in serum CRP levels. Naturopathic remedies for treating oral disease have been well documented in the medical and dental literature since early civilization, and have become more and more popular in recent years. We propose to study one such remedy, PERIORINSE. This remedy consists of a number of herbs, and has been shown to exhibit antibacterial and anti-inflammatory effects. Specifically, it has been shown to block the proteolytic effects seen in gingival inflammation . This study will evaluate the efficacy of this formulation, using currently accepted clinical testing protocols. A Random sample of 100 healthy volunteers who fulfill all inclusion criteria and no exclusion criteria, will be included in the study. Patients will randomly selected to one of 4 treatment groups: PERIORINSE (n=25), CPC (Cepacol) mouthwash (25 patients), Listerine mouthwash (n=25), and placebo (colored water) mouthrinse. Patients will be examined at baseline, and Gingival Index taken for all teeth. A blood specimen will be taken to measure CRP levels as well. Patients will be given a full dental prophylaxis which includes scaling and tooth polishing, and given rinsing instructions and reminded to cease all other oral hygiene methods including brushing, flossing, and rinsing with any other rinse for a period of 14 days. On day 14, patients will be re-examined and Gingival Index taken for all teeth. Patients will be given a full dental prophylaxis which includes scaling and tooth polishing and required to reinstitute their original oral hygiene regimen. CRP levels will be measured again, as well.

Overall Status Completed
Start Date 2009-06-01
Completion Date 2010-06-01
Primary Completion Date 2010-06-01
Phase Phase 1/Phase 2
Study Type Interventional
Primary Outcome
Measure Time Frame
Difference in the Gingival Index scores between the start and the end of the study 14 days
Secondary Outcome
Measure Time Frame
The difference in C-Reactive protein levels between the start and the end of the study. 14 days
Enrollment 94
Condition
Intervention

Intervention Type: Drug

Intervention Name: Herbal API

Description: mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.

Arm Group Label: PERIORINSE

Intervention Type: Drug

Intervention Name: Cepacol

Description: mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.

Arm Group Label: CPC

Intervention Type: Drug

Intervention Name: Listerine Antiseptic Mouth Rinse

Description: mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.

Arm Group Label: Listerine

Intervention Type: Drug

Intervention Name: placebo mouthwash

Description: colored water mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.

Arm Group Label: placebo

Eligibility

Criteria:

Inclusion Criteria: - Age 14-75. - Clinical diagnosis of Gingivitis as measured by the Gingival index ≤ 0.5 - Healthy volunteer willing to cease all oral hygiene methods except for the mouthrinse for a period of three weeks. - Have at least 24 teeth in their mouth Exclusion Criteria: - Pregnant or planning to become pregnant during the study period. - Periodontal pockets greater than 5mm in 3 or more areas. - History of periodontal treatment within the last month. - Antibiotic treatment within the last month - Use of any antimicrobial mouthrinse within the last month. - Participation in another trial within one month prior to the study. - Inability to comply with the trial protocol by not rinsing with mouthrinse 20% of time. - Inability to comply, brushing the teeth or using another mouthrinse during the study period. - Systemic Disease. - On antibiotic or anti-inflammatory medication - Cigarette-smoking

Gender:

All

Minimum Age:

14 Years

Maximum Age:

75 Years

Healthy Volunteers:

Accepts Healthy Volunteers

Overall Official
Last Name Role Affiliation
Menachem Oberbaum, MD Principal Investigator Shaare Zedek Medical Center
Location
Facility: Shaare Zedek Medical Center
Location Countries

Israel

Verification Date

2012-07-01

Responsible Party

Type: Principal Investigator

Investigator Affiliation: Shaare Zedek Medical Center

Investigator Full Name: Menachem Oberbaum

Investigator Title: Director, Center for Integrative Complementary Medicine

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 4
Arm Group

Label: PERIORINSE

Type: Experimental

Description: naturopathic remedy

Label: CPC

Type: Active Comparator

Description: Cepacol, standard anti-bacterial mouthwash

Label: Listerine

Type: Active Comparator

Description: standard anti-bacterial mouthwash

Label: placebo

Type: Placebo Comparator

Description: colored water

Study Design Info

Allocation: Randomized

Intervention Model: Parallel Assignment

Primary Purpose: Treatment

Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News